Related Experiment Video
Updated: May 12, 2025
Murine Model of Intestinal Ischemia-reperfusion Injury
Published on: May 11, 2016
Protective effects of KML29 in intestinal ischemia-reperfusion injury: An experimental study
İbrahim Çaltekin1, Ali Aygün1, Adem Köksal1
1Department of Emergency Medicine, Ordu University Faculty of Medicine, Ordu-Türkiye.
Background:
Acute mesenteric ischemia (AMI) is a potentially fatal vascular emergency that results in tissue damage due to ischemia-reperfusion injury (IRI) and is difficult to diagnose and treat in its early stages. Monoacylglycerol lipase inhibitors have demonstrated protective effects against ischemia-reperfusion injury due to their antioxidant and anti-inflammatory properties. This study aimed to evaluate the effects of KML29, a potent and selective monoacylglycerol lipase inhibitor, on intestinal IRI.
Methods:
Thirty-two female Wistar albino rats were divided into four groups: Group 1 - Sham; Group 2 - Ischemia/Reperfusion (IR); Group 3 - IR + KML29 (2 mg/kg); and Group 4 - IR + KML29 (10 mg/kg). Intestinal ischemia-reperfusion was induced by occluding the superior mesenteric artery for 45 minutes, followed by 60 minutes of reperfusion. KML29 was administered intraperitoneally to Groups 3 and 4 at doses of 2 mg/kg and 10 mg/kg, respectively, 30 minutes prior to surgery. Intestinal IRI was evaluated using histopathological and biochemical parameters.
Results:
Treatment with 10 mg/kg KML29 was associated with improved histopathological findings in the IR group (p=0.0001). Elevated levels of nuclear factor kappa B (NF-kB), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and transforming growth factor-beta 1 (TGF-β1) observed in the IR group were significantly reduced following administration of 10 mg/kg KML29 (p=0.0001). Additionally, treatment with both 2 mg/kg and 10 mg/kg doses of KML29 significantly reduced the number of apoptotic cells in the IR group (p=0.0001).
Conclusion:
In conclusion, this study demonstrated that treatment with both doses of KML29 (2.5 mg/kg and 10 mg/kg) significantly reduced the number of apoptotic cells and inflammatory markers, and improved histopathological findings in the intestinal tissues of rats subjected to IR. With its anti-inflammatory and anti-apoptotic properties, KML29 may represent a novel therapeutic option for the treatment of mesenteric ischemia.
Insights
KML29, a monoacylglycerol lipase inhibitor, significantly reduced inflammation and cell death in rat models of acute mesenteric ischemia. This suggests KML29 as a potential new treatment for this dangerous vascular condition.
Area of Science:
- Vascular Surgery
- Gastroenterology
- Pharmacology
Background:
- Acute mesenteric ischemia (AMI) is a critical vascular emergency with high mortality.
- Ischemia-reperfusion injury (IRI) exacerbates tissue damage in AMI.
- Monoacylglycerol lipase (MGL) inhibitors show promise due to antioxidant and anti-inflammatory effects.
Purpose of the Study:
- To investigate the therapeutic potential of KML29, a selective MGL inhibitor, in mitigating intestinal IRI.
- To evaluate KML29's impact on histopathological and biochemical markers of intestinal injury.
Main Methods:
- Thirty-two female Wistar albino rats were used, divided into sham, ischemia/reperfusion (IR), and IR + KML29 (2 mg/kg or 10 mg/kg) groups.
- Intestinal IRI was induced via superior mesenteric artery occlusion followed by reperfusion.
- KML29 was administered intraperitoneally 30 minutes before surgery; outcomes assessed via histopathology and biochemistry.
Main Results:
- The 10 mg/kg KML29 dose significantly improved intestinal histopathology in the IR group (p=0.0001).
- KML29 treatment markedly reduced elevated levels of inflammatory markers including NF-kB, TNF-α, IL-1β, and TGF-β1 (p=0.0001).
- Both KML29 doses significantly decreased apoptotic cell counts in the injured intestinal tissue (p=0.0001).
Conclusions:
- KML29 treatment, at both 2.5 mg/kg and 10 mg/kg, effectively reduced apoptosis and inflammation.
- KML29 demonstrated significant improvements in intestinal histopathology following IR.
- KML29 exhibits anti-inflammatory and anti-apoptotic properties, positioning it as a potential novel therapeutic for mesenteric ischemia.
